Transforming Diabetes Care: Pharmacist-Led Education and Its Impact on Patient Knowledge, Self-Management, and Health Outcomes

Transforming Diabetes Care: Pharmacist-Led Education and Its Impact on Patient Knowledge, Self-Management, and Health Outcomes

This interventional study is to evaluate the impact of pharmacist-led education on diabetic patients' knowledge, self-management, and overall health outcomes. Participants in this study will attend pharmacist-led educational sessions designed to improve their understanding of diabetes and self-care practices. Researchers will assess changes in patients' knowledge, self-management behaviors, and clinical health markers before and after the intervention. The study will compare pre- and post-intervention results to determine the effectiveness of pharmacist-led education in transforming diabetes care.

The purpose of this study is to investigate whether pharmacist-led education can enhance the knowledge, self-management behaviors, and health outcomes of diabetic patients. Effective diabetes management requires a comprehensive understanding of the disease, adherence to lifestyle modifications, and consistent monitoring of health indicators. Poor knowledge and suboptimal self-care can lead to inadequate glycemic control, complications, and reduced quality of life. This study will evaluate the impact of pharmacist-led educational interventions on patients' motivation, diabetes-related knowledge, and self-care behaviors, as well as their effects on clinical outcomes, including improved HbA1c levels, reduced hypo- and hyperglycemic episodes, and enhanced patient satisfaction. By addressing these critical aspects, the study aims to highlight the transformative role of pharmacist-led education in advancing diabetes care and fostering sustainable, patient-centered healthcare practices.

Inclusion Criteria:

• We will include all confirmed diabetic patients who visit the SIH endocrinology OPD Clinic during the study duration.

  • Both male and female patients visiting the Endocrinology Unit of the hospital will be eligible.
  • Patients with HbA1c levels greater than 8% will be included.
  • Both follow-up and newly diagnosed patients will be considered.
  • Patients who sign the informed consent form will be enrolled in the study.

Exclusion Criteria:

• We will exclude patients with gestational diabetes mellitus (GDM).

  • Patients with central obesity will not be included in the study.
  • Type 1 diabetes mellitus (DM) patients under the age of 20 will be excluded.
  • Patients with inadequate medical history will be excluded from participation.
  • Patients with HbA1c levels less than 8% will not be included.
  • Patients who do not provide informed consent or express a lack of interest in the study will be excluded.